GlaxoSmithKline shares rise on FDA approval of Breo Ellipta

GlaxoSmithKline's shares rose Thursday after the healthcare company announced US approval of Breo Ellipta, a treatment for chronic obstructive pulmonary disease (COPD).

Breo Ellipta, once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with COPD, was given the green light from the Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee.

The committee voted that the efficacy and safety data provide substantial evidence to support approval of the medication. The company submitted a new drug application to the FDA for approval of Breo last July.

"We are pleased with the outcome of today's meeting," said President of GlaxoSmithKline Pharmaceuticals, Patrick Vallance.

"COPD is a debilitating and progressive disease. Its symptoms are often severe and can have a huge impact on patients' lives. This positive recommendation is a crucial first step towards making Breo Ellipta available for appropriate COPD patients across the US.

"We look forward to a final decision from the FDA later this year."

RD